Randomized controlled trial of deutetrabenazine for tardive dyskinesia -

Randomized controlled trial of deutetrabenazine for tardive dyskinesia
Information type: Randomised controlled trials
Source: Neurology
Specialities: Musculo-skeletal disorders
Summary
In this study of 117 patients with moderate to severe tardive dyskinesia, deutetrabenazine resulted in a larger reduction in Abnormal Involuntary Movement Scale score than placebo at week 12 (least-squares mean [standard error] −3.0 [0.45] vs −1.6 [0.46], p=0.019).
UKMi comment
The US FDA granted deutetrabenazine Priority Review for treatment of tardive dyskinesia in March 2017 and it was approved for Huntington’s disease in the US in April 2017. There is currently no indication of EU/UK developmental status.
Related links: